Matrix Pharma regulatory update

MATX received a non-approvable letter from the FDA, which characterized as inadequate the information submitted by the company for AccuSite Injectable Gel for the treatment

Read the full 254 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE